UDG.L

UDG Healthcare Plc
Goldman Sachs (EPT) - Form 38.5a - UDG Healthcare plc - Amendment
16th August 2021, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6666I
GoldmanSachs International
13 August 2021
 

Amendment - due to the amendment of Derivative transactions, the disclosure made on 12 July for dealings on 11 July has been updated. Section 2(b) has been updated.

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

(GS) GOLDMAN SACHS INTERNATIONAL

Company dealt in

UDG HEALTHCARE PLC

Class of relevant security to which the dealings being disclosed relate (Note1)

EUR 0.05 ordinary shares

Date of dealing

11 August 2021

 

2.    DEALINGS (Note 2)

(a) Purchases and sales

 

Total number of relevant securities acquired

Highest price paid (Note 3)

Lowest price paid (Note 3)

205,952

10.7900 GBP

10.7750 GBP

 

Total number of relevant securities disposed

Highest price received (Note 3)

Lowest price received (Note 3)

7,997

10.7850 GBP

10.7750 GBP

 

(b) Derivatives transactions (other than options transactions)

 

Product name, e.g. CFD

Nature of transaction  (Note 4)

Number of relevant securities  (Note 5)

Price per unit  (Note 3)

CFD

Increasing a short position

80,304

10.7825 GBP

CFD

Reducing a short position

7,682

10.7840 GBP

CFD

Increasing a short position

125,000

10.7859 GBP

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option

Writing, selling,  purchasing, varying etc.

Number of securities to which the option relates  (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit  (Note 3)

 

 

 

 

 

 

 

 

(ii)            Exercising

 

Product name,e.g. call option

Number of securities

Exercise price per unit  (Note 3)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated. 

NONE

 

Date of disclosure

13 August 2021

Contact name

Paul Grainger and Kashif Rafiq

Telephone number

+44(20) 7552 9835 / +44(20) 7051 0547

Name of offeree/offeror with which connected

UDG HEALTHCARE PLC

Nature of connection (Note 6)

Advisor to Offeree

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEDKNBNOBKDBFD ]]>
TwitterFacebookLinkedIn